Skip to content
TrialScanner

NCT03420430

Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care

No phase registeredNo longer availableGNLXLead

Registry record

Lead sponsor
Genelux Corporation
Conditions
Advanced Stage Cancer (Solid Tumor Disease for 4 Patients); Acute Myeloid Leukemia (6 Patients)
Primary completion
Not registered
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03420430 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03420430: Expanded Access to Provide... | TrialScanner